
Fate Therapeutics (FATE) Stock Forecast & Price Target
Fate Therapeutics (FATE) Analyst Ratings
Bulls say
Fate Therapeutics is expected to see a positive future, with a market value of approximately $814 million by the end of 2026, taking into consideration their projected cash reserves and investments. The company's prospects are deemed favorable, with potential success in their program FT819 for SLE and risks such as safety and regulatory concerns, partnership risks, and dilution in the medium-term. Hence, this company has potential for long-term growth and can present a good investment opportunity.
Bears say
Fate Therapeutics is facing a negative outlook due to its lack of diversity in its pipeline and high-risk experimental treatments in the clinical stage. Additionally, the company's financials may be impacted by its extensive investment in research and development, which may not yield positive results in the future. Furthermore, the company's focus on treating autoimmune disorders with immunotherapies may also face regulatory challenges, leading to potential delays in bringing products to market.
This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Fate Therapeutics (FATE) Analyst Forecast & Price Prediction
Start investing in Fate Therapeutics (FATE)
Order type
Buy in
Order amount
Est. shares
0 shares